446866-83-7

Basic information

• Product Name: 3-(MORPHOLINOMETHYL)BENZALDEHYDE
• Synonyms: 4-(3-CARBOXALDEHYDEBENZYL)MORPHOLINE;3-MORPHOLIN-4-YLMETHYL-BENZALDEHYDE;3-(MORPHOLINOMETHYL)BENZALDEHYDE;3-(Morpholin-4-ylmethyl)benzaldehyde 95+%;3-(morpholin-4-ylmethyl)benzaldehyde(SALTDATA: FREE);4-(3-Formylbenzyl)morpholine
• CAS NO: 446866-83-7
• Molecular Formula: C₁₂H₁₅NO₂
• Molecular Weight: 205.25
• Mol File: 446866-83-7.mol

Chemical Properties

• Melting Point: 63 °C
• Boiling Point: 321.9 °C at 760 mmHg
• Flash Point: 148.5 °C
• Appearance: /
• Density: 1.149 g/cm³
• Vapor Pressure: 0.000289mmHg at 25°C
• Refractive Index: 1.581
• CAS DataBase Reference: 3-(MORPHOLINOMETHYL)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(MORPHOLINOMETHYL)BENZALDEHYDE(446866-83-7)
• EPA Substance Registry System: 3-(MORPHOLINOMETHYL)BENZALDEHYDE(446866-83-7)

Safety Data

• Hazard Codes: C
• HazardClass: IRRITANT
• Hazardous Substances Data: 446866-83-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(MORPHOLINOMETHYL)BENZALDEHYDE is used as a building block for the synthesis of heterocyclic compounds, which are essential in the development of new pharmaceuticals. Its potential biological and pharmacological properties make it a promising candidate for further research and application in drug discovery.
Used in Agrochemical Industry:
3-(MORPHOLINOMETHYL)BENZALDEHYDE is used as an active ingredient in the formulation of antimicrobial and antifungal agents. Its antimicrobial properties make it a valuable component in the development of preservatives and other agrochemical products to protect crops and enhance agricultural productivity.
Used in Dye Industry:
3-(MORPHOLINOMETHYL)BENZALDEHYDE is used in the production of dyes due to its chemical properties. Its versatility in synthesis allows for the creation of various dye compounds, contributing to the diversity of colorants available in the market.

InChI:InChI=1/C12H15NO2/c14-10-12-3-1-2-11(8-12)9-13-4-6-15-7-5-13/h1-3,8,10H,4-7,9H2

Upstream product

• 823-78-9 meta-bromobenzyl bromide 
• 68-12-2 N,N-dimethyl-formamide 
• 364793-82-8 4-(3-bromobenzyl)morpholine 
• 857283-91-1 C₁₂H₁₄N₂O 
• 28188-41-2 m-(bromomethyl)benzonitrile 

Downstream Products

• 1029800-54-1 (R)-2-(3-morpholin-4-ylmethyl-phenyl)-thiazolidine-4-carboxylic acid 
• 1095381-30-8 4-(3-(6-bromo-7-(4-(4-chlorobenzyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)benzyl)morpholine 
• 942949-16-8 6-Bromo-2-(3-morpholin-4-ylmethyl-phenyl)-7-(4-pyridin-3-ylmethyl-piperazin-1-yl)-3H-imidazo[4,5-b]pyridine 
• 1402709-73-2 4-(3-(6-chloro-7-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)benzyl)morpholine 

Relevant articles and documents

Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility

While progress has been made in treating cancer, cytotoxic chemotherapeutic agents are still the most widely used drugs and are associated with severe side-effects. Drugs that target unique molecular signalling pathways are needed for treating cancer with low or no intrinsic toxicity to normal cells. Our goal is to target hypoxic tumours and specifically the hypoxia inducible factor (HIF) pathway for the development of new cancer therapies. To this end, we have previously developed benzopyran-based HIF-1 inhibitors such as arylsulfonamide KCN1. However, KCN1 and its earlier analogs have poor water solubility, which hamper their applications. Herein, we describe a series of KCN1 analogs that incorporate a morpholine moiety at various positions. We found that replacing the benzopyran group of KCN1 with a phenyl group with a morpholinomethyl moiety at the para positions had minimal effect on potency and improved the water solubility of two new compounds by more than 10-fold compared to KCN1, the lead compound.

BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY

A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodege

AMINO-FUNCTIONAL CHALCONES

The invention provides novel amino-functionalised chalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is also discl